AstraZeneca Divests Antimalarials to Alliance Pharmaceuticals; Plexus Ventures Assisted AstraZeneca with this Transaction

Aug 2, 2012

London, United Kingdom — Plexus Ventures is pleased to announce the successful completion of a divestment project. Plexus provided transaction services to AstraZeneca UK Limited in the divesture of three of the company’s antimalarial brands — PaludrineTM, AvloclorTM and SavarineTM — to Alliance Pharmaceuticals Limited. The products are sold mainly in the UK and France.

Michael O’Sullivan, Managing Director of Plexus Ventures UK office, commented: We are pleased to have successfully completed our first transaction for AstraZeneca. Our strong performance on behalf of our multinational clients like AstraZeneca has led to an ever increasing number of divestment assignments for Plexus Ventures. We thank AstraZeneca for their confidence in us.

About Plexus Ventures

Plexus Ventures, founded over 30 years ago, is a leading corporate and business development consultancy for the healthcare industry. Plexus assists clients of all sizes and capabilities to achieve their strategic business development objectives, advising on M&A, asset divestments, licensing and partnership arrangements. Plexus’ industry professionals are conveniently located in the United States, Europe and Asia-Pacific markets, enabling Plexus to benefit its clients with both local knowledge and global reach.